Cholesterol-lowering treatment in chronic kidney disease: multistage pairwise and network meta-analyses

• Autores: Herrera-Gómez, Francisco, Chimeno, M. Montserrat, Martín-García, Débora, Lizaraso-Soto, Frank, Maurtua-Briseno-Meiggs, Álvaro, Grande-Villoria, Jesús, Bustamante-Munguira, Juan, Alamartine, Eric, Vilardell, Miquel, Ochoa-Sangrador, Carlos, Álvarez, F. Javier
• Formato: artículo
• Fecha de Publicación: 2019
• Institución: Universidad de San Martín de Porres
• Repositorio: USMP-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.usmp.edu.pe:20.500.12727/6096
• Enlace del recurso: https://hdl.handle.net/20.500.12727/6096; https://doi.org/10.1038/s41598-019-45431-5
• Nivel de acceso: acceso abierto
• Materia: Colesterol; Insuficiencia renal crónica; Revisión de la investigación por pares; Metaanálisis; https://purl.org/pe-repo/ocde/ford#3.02.00

Pairwise and network meta-analyses on the relationship between the efficacy of the use of statins with or without ezetimibe and reductions in low-density lipoprotein cholesterol (LDLc) and C-reactive protein (CRP) in patients with chronic kidney disease (CKD) are presented. In the pairwise meta-analysis, statins with or without ezetimibe were shown to be efficacious in reducing major adverse cardiovascular events (MACE) in patients with CKD and an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m2, in the context of both primary prevention [odds ratio (OR)/95% confidence interval (95% CI)/I2/number of studies (n): 0.50/0.40-0.64/0%/6] and primary/secondary prevention (0.66/0.57-0.76/57%/18). However, in the Bayesian network meta-analysis, compared to the placebo, only atorvastatin 80 mg daily and atorvastatin and rosuvastatin at doses equivalent to simvastatin 20 mg daily reduced the odds of MACEs in this patient population. The network meta-analysis for LDLc and CRP treatment objectives also showed that, regardless of eGFR and excluding dialysis patients, the number of MACEs decreased in patients with CKD, with reductions in both LDLc and CRP of less than 50% (surface under the cumulative ranking (SUCRA)/heterogeneity (vague)/n: 0.77/0.14/3). The evaluation of the benefits of drugs may lead to individualized therapy for CKD patients: Cholesterol-lowering treatment for CKD patients with high levels of both LDLc and CRP is suggested.